Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
复制标题
多孔PLGA微球协同递送阿霉素和紫杉醇用于肺部吸入治疗
DOI：
10.1016/j.ejpb.2014.09.012
复制
发表时间：
2014-11-01
影响因子：
4.9
通讯作者：
Chen, Xuesi
中科院分区：
文献类型：
--
作者：
Feng, Tianshi;Tian, Huayu;Chen, Xuesi
制备了载阿霉素（DOX）和紫杉醇（PTX）的PLGA多孔微球，用于转移性肺癌的原位治疗。研究了组合药物对B16 F10细胞的协同作用，以获得用于体内研究的最佳处方。当联合用药中DOX占多数时，联合用药表现出很强的协同作用，而当PTX占多数时，联合用药表现出中等程度的拮抗作用。DOX和PTX以5/1的摩尔比组合在游离形式下显示出最佳的协同治疗效果。而当药物与PLGA的摩尔比为2：1时，由于药物释放速率的差异，药物在PLGA微球中表现出更强的协同作用。体内研究证实了DOX和PTX在最佳摩尔比下的协同作用。这些结果表明，在多孔PLGA微球中双重包封DOX和PTX将是一种有前途的长期有效治疗肺癌的技术。(C)2014爱思唯尔有限公司版权所有。
PLGA porous microspheres loaded with doxorubicin (DOX) and paclitaxel (PTX) were developed for in situ treatment of metastatic lung cancer. The synergistic effect of the combined drugs was investigated against B16F10 cells to obtain the optimal prescription for in vivo studies. The combination therapy showed great synergism when DOX was the majority in the combination therapy, while they showed moderate antagonism when PTX is in major. The combination of DOX and PTX at a molar ratio of 5/1 showed the best synergistic therapeutic effect in the free form. However, the drugs exhibited more synergism in the PLGA microspheres at a molar ratio of 2/1, due to the difference in drug release rate. The in vivo study verified the synergism of DOX and PTX at the optimal molar ratio. These results suggested that dual encapsulation of DOX and PTX in porous PLGA microspheres would be a promising technology for long effective lung cancer treatment. (C) 2014 Elsevier B.V. All rights reserved.